From April 1 to June 30, 2026, Health Canada approved 15 new drug submissions (8 pharmaceuticals, 7 biologics) and 481 new medical devices, including 22 Class IV medical devices, which present the greatest potential risk. During this period, Health Canada also approved 31 generic drugs and 10 biosimilar drugs.